Indoleamine 2, 3-dioxygenase 1 (IDO; IDO1) is expressed in > FoxP3+). Since IDO is canonically characterized as a rate-limiting enzyme that metabolizes the essential amino acid, tryptophan (Trp), into kynurenine (Kyn), the depletion of Trp and/or accumulation of Kyn has been the presumed mechanism of how IDO suppresses the anti-GBM immune response. However, our work has challenged this hypothesis, and here we provide a comprehensive update of IDO effects in adults with GBM.
|Original language||English (US)|
|Title of host publication||Immunotherapeutic Strategies for the Treatment of Glioma|
|Number of pages||25|
|State||Published - Jan 1 2021|
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Biochemistry, Genetics and Molecular Biology(all)